Roots Analysis has announced the addition of the “Antibody ContractManufacturing Market, 2020-2030” report to its listof offerings.
Althoughbiopharmaceuticals offer significant profit margins and have been proven to beeffective in treating a myriad of diseases, they are generally associated withhigh costs of development and complex manufacturing protocols; this is true forantibody-based products as well. Presently, there are a number of companiesthat claim to offer end-to-end solutions, ranging from antibody development tocommercial production. Further, prevalent trends suggest that sponsor companiesare likely to continue relying on contract service providers for variousaspects of antibody-based product development and manufacturing.
To order this 285+ page report, which features 100+ figuresand 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Key Market Insights
Over100 CMOs presently claim to offer manufacturing services for antibodies
The antibody contractmanufacturing market is currently dominated by the presence of small andmid-sized companies, which represent 70% of the industry stakeholders. It is alsoworth highlighting that more than 55% of CMOs claim to have the capabilities tomanufacture antibodies across all scales of operation (preclinical, clinicaland commercial).
More than 90% service providers are focused on theproduction of monoclonal antibodies
However, playersbased in Asia are now increasingly focusing on the development of bispecificantibodies for therapeutic use. It worth highlighting that close to 20% of theCMOs engaged in this domain claim to offer manufacturing services for both bispecificantibodies and antibody fragments.
Europe has emerged as a key manufacturing hub for antibody-basedproducts
More than 120manufacturing facilities have been established by various players, worldwide;of these, 40% are in Europe. Additionally, 40% of the total installed capacity isin Europe, followed by Asia. Some of the prominent regions in Asia include (indecreasing order of number of manufacturing facilities) China, South Korea,India, Japan and Taiwan.
Morethan 90 partnership agreements have been inked between 2013 and 2019
Majority of theseagreements were focused on manufacturing of various types of antibodies. Otherpopular types of collaboration models include process development andmanufacturing agreements (22%), product development and manufacturingagreements (10%) and licensing agreements (7%).
Multipleexpansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of suchinitiatives were reported to be focused on the expansion of manufacturing facilities,followed by building new facilities (38%). It is worth noting that close to 50%of the total number of expansion initiatives were undertaken in Europe, ofwhich, 25% were in the UK.
Demandfor therapeutic antibodies is anticipated to grow at a CAGR of 10%, during2020-2025
Giventhe fact that there are a number of antibody-based products in the market, the commercialdemand for antibodies is significantly higher than the clinical demand. Acrossthe three major global regions, North America represent over half of theoverall global manufacturing demand for antibodies.
NorthAmerica and Europe are anticipated to capture over 70% of the market share by2030
However, the marketin the Asia is anticipated to grow at a relatively faster rate. Further,presently, more than 90% of the antibodies are being developed using mammalianexpression systems, and this trend is unlikely to change significantly in shortto mid-term.
To request a sample report - https://www.rootsanalysis.com/reports/295/request-sample.html
KeyQuestions Answered
§ Who are the leading CMOs engaged in the production of antibody-basedtherapeutics?
§ Whatkind of partnership models are commonly adopted by stakeholders in thisindustry?
§ Whatis the annual clinical and commercial demand for antibody-based products?
§ Whatis the current installed capacity for manufacturing of antibodies?
§ Whatare the various expansion initiatives undertaken by antibody CMOs?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
The USD 17 billion (by 2030) financial opportunitywithin the antibody contract manufacturing market has been analyzed across thefollowing segments:
§ Typeof Antibodies
§ MonoclonalAntibodies
§ BispecificAntibodies
§ ADCs
§ Others
§ Company Size
§ Small
§ Mid-sized
§ Large/ Very Large
§ Scaleof Operation
§ Preclinical/ Clinical
§ Commercial
§ Typeof expression system used
§ Mammalian
§ Microbial
§ Keygeographical regions
§ NorthAmerica
§ Europe
§ Asiaand RoW
The report featuresinputs from eminent industry stakeholders, according to whom antibodytherapeutics developers are increasingly outsourcing their manufacturing operationsowing to complex nature of the overall process, as well as the high investmentsassociated with setting-up in-house expertise. The report includes detailedtranscripts of discussions held with the following experts:
§ DietmarKatinger (Chief Executive Officer, Polymun Scientific)
§ DavidC Cunningham (Director, Corporate Development, Goodwin Biotechnology)
§ ClaireOtjes (Marketing Manager, Batavia Biosciences)
The research coversprofiles of key players that offer manufacturing services for antibodies,featuring a company overview, information on their respective service portfolios,manufacturing facilities and capabilities, and an informed future outlook.
§ AGCBiologics
§ Aldevron
§ AMRI
§ BoehringerIngelheim BioXcellence
§ EmergentBioSolutions
§ EurofinsCDMO
§ FUJIFILMDiosynth Biotechnologies
§ KBIBiopharma
§ Lonza
§ NittoAvecia Pharma Services
§ Novasep
§ PierreFabre
§ SamsungBioLogics
§ Synthon
§ ThermoFisher Scientific
To request a customize report - https://www.rootsanalysis.com/reports/antibody-cmo-market/request-customization.html
You may also beinterested in the following titles:
1. Bispecific Antibody Therapeutics Market
2. Antibody Drug Conjugates (ADCs)
3. Antibody Drug Conjugates Market
4. Cloud-based Solutions for Drug Discovery, Development andManufacturing Market
6. Alpha-1 Antitrypsin Deficiency (AATD)
Contact:
Gaurav Chaudhary
+1(415) 800 3415
+44(122) 391 1091
